The results of research awards from two agencies today demonstrate the VPC's successful translation of basic research into discoveries that are moving to clinical applications.
July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.
The Best of the AACR Journals collection 2016 highlights the most-cited articles published in 2015 across the AACR journals.
On Saturday September 23, 2017 the University of British Columbia and the Vancouver Prostate Centre’s Prostate Cancer Supportive Care Program will be participating in the 17th Annual Pacific Northwest Prostate Cancer Symposium. Click here to see the agenda (PDF opens in new tab). In conjunction with the OHSU Knight Cancer Institute and the University of Washington School of Medicine, this live symposium is for patients, their families and health care professionals...
The Journal of the National Cancer Institute today published a landmark multi-institutional study describing the first comprehensive comparison of blood-based tumour biopsy versus metastatic tissue biopsy for lethal prostate cancer.
Congratulations to Drs. Collins, Daugaard & Wang on being awarded five-year grants in the CIHR Project Grant: Fall 2016 competition. Dr. Wang is also a co-investigator on a five-year grant awarded to Dr. He at University Health Network (Toronto). Congratulations also to Dr. William Morris of the BC Cancer Agency and his research team, including our Centre's Dr. Alan So, on being awarded a six-year grant in the same competition.
UBC Media release: April 20, 2017
A drug created from a malaria protein stopped tumour growth of chemotherapy-resistant bladder cancer, offering hope for cancer patients not responding to standard treatments.
Friday, April 7, 2017 9:45 AM
Research excellence at the Vancouver Prostate Centre was demonstrated at the American Association for Cancer Research (AACR) annual meeting, April 1 - 5, 2017.
Dr. Alastair Davies & Dr. Amina Zoubeidi present their work in the Tumor Stem Cell Biology session (April 4, 2017), in a talk titled "EZH2 reprogramming confers intrinsic stem cell properties and developmental plasticity driving neuroendocrine prostate cancer".
A study led by Drs. Kim Chi & Alex Wyatt demonstrated that metastatic castration-resistant prostate cancer patients with germline DNA repair defects respond poorly to androgen receptor-targeted therapy.